4-Boc-哌嗪-2-羧酸 | 128019-59-0

• 物质功能分类: 医药中间体 - 哌嗪类化合物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 4-Boc-哌嗪-2-羧酸
• 中文别名: (±)-4-Boc-哌嗪2-羰酸；4-羟基-6-(三氟甲氧基)-2-(三氟甲基)喹啉；4-Boc-2-哌嗪甲酸；1-叔丁氧羰基哌嗪-3-羧酸；4-叔丁氧羰基哌嗪-2-羧酸；1-BOC-3-甲酸哌嗪；4-叔丁氧羰基哌嗪-2-甲酸；1-BOC-哌嗪-3-羧酸；N-4-Boc-2-哌嗪甲酸；4-N-叔丁氧羰基-哌嗪-2-羧酸；4-N-BOC-哌嗪-2-羧酸；4-Boc-哌嗪-2-甲酸；N-4-BOC-2-哌嗪甲酸；4-boc-哌嗪-2-羧酸
• 英文名称: 4-(tert-butoxycarbonyl)piperazine-2-carboxylic acid
• 英文别名: 4-Boc-piperazine-2-carboxylic acid；piperazine-1,3-dicarboxylic acid 1-tert-butyl ester；4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-ium-2-carboxylate
• CAS: 128019-59-0
• 化学式: C₁₀H₁₈N₂O₄
• mdl: MFCD01076218
• 分子量: 230.264
• InChiKey: YRYAXQJXMBETAT-UHFFFAOYSA-N

物化性质

• 熔点：
  231-239 °C
• 沸点：
  371.8±37.0 °C(Predicted)
• 密度：
  1.193±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  78.9
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S26,S36/37,S36/37/39
• 危险品运输编号：
  NONH for all modes of transport
• 海关编码：
  2933599090
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 危险类别：
  IRRITANT
• 危险标志：
  GHS07
• 危险性描述：
  H317,H319
• 危险性防范说明：
  P280,P305 + P351 + P338
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-N-Boc-piperazine-2-carboxylic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H317: May cause an allergic skin reaction
H319: Causes serious eye irritation
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-N-Boc-piperazine-2-carboxylic acid
CAS number: 128019-59-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
This product should be handled only by, or under the close supervision of, those properly qualified
Handling:
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H18N2O4
Molecular weight: 230.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-Boc-哌嗪-2-羧酸 在 dimethyl sulfide borane 、 水 、 三乙酰氧基硼氢化钠 、 三乙胺 、 pyridinium chlorochromate 、 三氟乙酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 2.16h， 生成
  参考文献：
  名称：

  新型N-芳基哌嗪CXCR4拮抗剂的发现

  摘要：

  描述了具有取代的哌嗪作为苯并咪唑替代物的一系列新的CXCR4拮抗剂。这些化合物在CXCR4介导的功能和HIV检测中显示出微摩尔至纳摩尔的效价，即在MAGI-CCR5 / CXCR4细胞中抑制X4 HIV-1 IIIB病毒和在Schem- 1细胞中抑制SDF-1诱导的钙释放。SAR的初步研究导致鉴定出一系列N-芳基哌嗪为最有效的化合物。结果表明，SAR表示芳香环的类型和位置，以及接头和立体化学的类型对于活性均很重要。对几种先导化合物进行分析表明，一种（49b）降低了对CYP450和hERG的敏感性，同时考虑了SDF-1和HIV效力（6–20 nM）时获得了最佳的总体特征。

  DOI：

  10.1016/j.bmcl.2015.04.036
• 作为产物：
  描述：

  2-哌嗪羧酸盐酸盐 、 二碳酸二叔丁酯 在 sodium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 生成 4-Boc-哌嗪-2-羧酸
  参考文献：
  名称：

  含二胺外排泵抑制剂类似物的理化性质，体外活性与药代动力学特征之间的关系。

  摘要：

  在体外增强活性，体内稳定性和急性毒性方面优化含二胺的外排泵抑制剂后，我们解决了如何控制该系列药代动力学特性的问题。在大鼠中静脉内给药后，与血清中的组织水平相比，MC-04,124（先导化合物）的组织水平较高且持续时间较长。系统地改变了该化合物类似物的亲脂性和碱性，并探讨了其对药效和药代动力学的影响。在任何检查的活性类似物中，组织与血清中药物水平的比率均未显着降低。

  DOI：

  10.1016/j.bmcl.2003.07.030
• 作为试剂：
  描述：

  Hydron; 2-piperazinecarboxylic acid; dichloride 、 碳酸氢钠 、 二碳酸二叔丁酯 在 乙酸乙酯 、 正丁醇 、 4-Boc-哌嗪-2-羧酸 作用下， 以 dioxane-water 、 水 为溶剂， 反应 8.0h， 生成 4-Boc-哌嗪-2-羧酸
  参考文献：
  名称：

  Oxadiazole HDAC inhibitors

  摘要：

  本发明涉及具有以下式的化合物：其中X1，X2，X3，R1，R2，Y，Q，X，B和L的定义如本文所述，并且涉及制备和使用这些化合物的方法。

  公开号：

  US08981084B2

文献信息

• [EN] BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION<br/>[FR] DÉRIVÉS BIS-HÉTÉROARYLIQUES EN TANT QUE MODULATEURS DE L'AGRÉGATION DES PROTÉINES
  申请人：NEUROPORE THERAPIES INC

  公开号：WO2017020010A1

  公开（公告）日：2017-02-02

  The present invention relates to certain bis-heteroaryl compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto- temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.

  本发明涉及某些双杂环芳基化合物，含有它们的药物组合物，以及使用它们的方法，包括用于预防、逆转、减缓或抑制蛋白聚集的方法，以及治疗与蛋白聚集相关的疾病的方法，包括帕金森病、阿尔茨海默病、路易体病、帕金森病伴痴呆、额颞型痴呆、亨廷顿病、肌萎缩侧索硬化和多系统萎缩等神经退行性疾病，以及包括黑色素瘤在内的癌症。
• Solid phase synthesis of n,n-disubstituted diazacycloalkylcarboxy derivatives
  申请人：Aventis Pharmaceuticals Inc.

  公开号：US07138526B1

  公开（公告）日：2006-11-21

  A method for the solid phase synthesis of N,N-disubstituted diazacycloalkylcarboxy derivatives of general formula (I) and (II) is claimed. Examples include piperazine-2-carboxamide. The method is applicable to the synthesis or large combinatorial libraries

  一种用于固相合成一般式（I）和（II）的N,N-二取代二氮杂环烷基羧酸衍生物的方法。示例包括哌嗪-2-羧酰胺。该方法适用于合成大型组合化合物库。
• Inhibitors of bace
  申请人：——

  公开号：US20030095958A1

  公开（公告）日：2003-05-22

  The present invention relates to inhibitors of aspartic proteinases, particularly, BACE. The present invention also relates to compositions thereof and methods therewith for inhibiting BACE activity in a mammal, and for treating Alzheimer's Disease and other BACE-mediated diseases.

  本发明涉及天冬氨酸蛋白酶抑制剂，特别是BACE。本发明还涉及其组合物和方法，用于在哺乳动物中抑制BACE活性，并用于治疗阿尔茨海默病和其他BACE介导的疾病。
• [EN] CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30<br/>[FR] HÉTÉROCYCLES CYANO-SUBSTITUÉS PRÉSENTANT UNE ACTIVITÉ EN TANT QU'INHIBITEURS DE L'USP30
  申请人：MISSION THERAPEUTICS LTD

  公开号：WO2018065768A1

  公开（公告）日：2018-04-12

  The present invention relates to cyano-substituted-heterocycles of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having utility in a variety of therapeutic areas including cancer and conditions involving mitochondrial dysfunction. (Formula (I))

  本发明涉及具有抑制去泛素化酶活性的Formula (I)的氰基取代杂环化合物，特别是泛素C-末端水解酶30或泛素特异性肽酶30（USP30），在包括癌症和涉及线粒体功能障碍等各种治疗领域中具有用途。（Formula (I)）
• Potent Synergy between Spirocyclic Pyrrolidinoindolinones and Fluconazole against<i>Candida albicans</i>
  作者：Ilandari Dewage Udara Anulal Premachandra、Kevin A. Scott、Chengtian Shen、Fuqiang Wang、Shelley Lane、Haoping Liu、David L. Van Vranken

  DOI：10.1002/cmdc.201500271

  日期：2015.10

  antifungal effect of fluconazole against Candida albicans. A diastereomer of this compound was synthesized, along with various analogues. Many of the compounds were shown to enhance the antifungal effect of fluconazole against C. albicans, some with exquisite potency. One spirocyclic piperazine derivative, which we have named synazo‐1, was found to enhance the effect of fluconazole with an EC50 value

  甲spiroindolinone，（1小号，3 - [R，3α [R，6α小号）-1-苄基-6'-氯-5-（4-氟苯基）-7'-甲基螺[1,2,3一个，6一个-tetrahydropyrrolo [3,4- c ]吡咯-3,3'-1 H-吲哚] -2'，4,6-三酮以前被报道可增强氟康唑对白色念珠菌的抗真菌作用。合成了该化合物的非对映异构体以及各种类似物。已显示许多化合物可增强氟康唑对白色念珠菌的抗真菌作用。s，有些具有精美的效能。发现一种螺环哌嗪衍生物，我们称为synazo-1，可增强氟康唑对敏感白念珠菌的EC 50值为300 p M的作用，对某些抗性菌株的作用低至2 n M。Synazo-1与氟康唑具有真正的协同作用，在测试菌株中FIC指数低于0.5。与抗真菌协同作用所需的浓度相比，Synazo-1在哺乳动物细胞中的毒性较低。